Humanwell Healthcare (Group) Co.,Ltd. (SHA:600079)

China flag China · Delayed Price · Currency is CNY
18.82
-0.03 (-0.16%)
At close: Dec 26, 2025
-20.69%
Market Cap30.72B
Revenue (ttm)24.18B
Net Income (ttm)1.43B
Shares Out1.63B
EPS (ttm)0.87
PE Ratio21.53
Forward PE13.23
Dividend0.47 (2.50%)
Ex-Dividend DateAug 19, 2025
Volume21,166,980
Average Volume35,933,827
Open18.81
Previous Close18.85
Day's Range18.76 - 19.03
52-Week Range16.73 - 24.05
Beta0.49
RSI48.11
Earnings DateMar 31, 2026

About SHA:600079

Humanwell Healthcare (Group) Co.,Ltd. researches, develops, produces, and sells pharmaceutical products in China and internationally. The company offers sufentanil citrate injection, an analgesic drug for combined anesthesia; remifentanil hydrochloride injection for induction of general anesthesia and maintenance of analgesia during general anesthesia; hydromorphone hydrochloride injection for patients who require opioid analgesia; nabuphine hydrochloride injection for use as an analgesic for anesthesia induction; alfentanil hydrochloride injec... [Read more]

Sector Healthcare
Founded 1988
Employees 17,650
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 600079
Full Company Profile

Financial Performance

In 2024, SHA:600079's revenue was 25.44 billion, an increase of 3.71% compared to the previous year's 24.52 billion. Earnings were 1.33 billion, a decrease of -37.70%.

Financial Statements

News

There is no news available yet.